Home > Boards > US Listed > Biotechs > Affimed Therapeutics (AFMD)

Affimed Places AFM11 (CD19/CD3-Targeting T cell Engager) Phase

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
LUPO BIANCO Member Profile
Member Level 
Followed By 49
Posts 2,027
Boards Moderated 0
Alias Born 09/25/10
160x600 placeholder
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/5/2020 7:00:54 AM
Affimed Announces Two New Appointments to Its Supervisory Board GlobeNewswire Inc. - 8/5/2020 6:30:00 AM
Affimed to Report Second Quarter 2020 Financial Results & Corporate Update August 11, 2020 GlobeNewswire Inc. - 8/4/2020 6:30:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/27/2020 4:37:35 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/10/2020 8:12:48 AM
Affimed Announces Annual General Meeting of Shareholders GlobeNewswire Inc. - 7/10/2020 6:30:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/23/2020 6:45:15 AM
Affimed Reports First Quarter 2020 Financial Results and Operational Progress GlobeNewswire Inc. - 6/23/2020 6:30:00 AM
Affimed Announces Presentation of Data on Genentech’s RO7297089 and AFM24, Both Innate Cell Engagers Developed from Affimed... GlobeNewswire Inc. - 6/22/2020 9:20:00 AM
Affimed Announces Successful Completion of First Dose Cohort in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of... GlobeNewswire Inc. - 6/17/2020 6:30:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 6/16/2020 10:56:13 AM
Affimed to Report First Quarter 2020 Financial Results & Corporate Update June 23, 2020; Company to Participate in Virtual BM... GlobeNewswire Inc. - 6/16/2020 6:30:00 AM
Affimed Announces Appointment of Angus Smith as Chief Financial Officer GlobeNewswire Inc. - 6/11/2020 6:30:00 AM
Affimed Highlights Study Design of its AFM13 REDIRECT Trial at the ASCO 2020 Virtual Meeting GlobeNewswire Inc. - 5/29/2020 8:05:00 AM
Affimed to Present at the Jefferies Virtual Healthcare Conference GlobeNewswire Inc. - 5/28/2020 5:00:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 5/26/2020 4:30:57 PM
Affimed Announces Abstracts on Innate Cell Engagers from its ROCK® Platform Accepted for Presentation at AACR Virtual Annual... GlobeNewswire Inc. - 5/15/2020 5:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/13/2020 4:33:10 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/13/2020 4:32:30 PM
Schedule 13g Edgar (US Regulatory) - 5/8/2020 8:10:57 AM
Annual and Transition Report (foreign Private Issuer) (20-f) Edgar (US Regulatory) - 4/28/2020 5:04:54 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 4/28/2020 6:49:07 AM
Affimed Reports 2019 Financial Results and Recent Operational Progress GlobeNewswire Inc. - 4/28/2020 6:35:00 AM
Affimed Announces First Patient Successfully Dosed in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of Advanced ... GlobeNewswire Inc. - 4/16/2020 7:30:00 AM
Affimed Provides COVID-19-Related Business Update and Announces Full Year 2019 Financial Results Conference Call on April 28,... GlobeNewswire Inc. - 4/2/2020 6:30:00 AM
LUPO BIANCO Member Level  Monday, 10/08/18 04:17:10 PM
Re: None
Post # of 234 
Affimed Places AFM11 (CD19/CD3-Targeting T cell Engager) Phase 1 Program on Clinical Hold
GLOBENEWSWIRE 4:15 PM ET 10/8/2018
Symbol Last Price Change
AFMD 4.63up +0.45 (+10.77%)
QUOTES AS OF 04:00:00 PM ET 10/08/2018
Heidelberg, Germany, October 8, 2018 - Affimed N.V. (AFMD) , a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies that harness the power of innate and adaptive immunity (NK and T cells), today announced that it has placed AFM11 (CD19/CD3-targeting T cell engager) on clinical hold, and has notified the global health authorities of its decision. AFM11 is being evaluated in two Phase 1 clinical studies for the treatment of patients with relapsed or refractory CD19 positive B-cell non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL). The clinical hold was initiated after the occurrence of Serious Adverse Events (SAEs) in three patients, which included a death in the ALL study and two life-threatening events in the NHL study.

The SAEs occurred in patients enrolled in the highest dose cohorts of each study. Thirty-three patients have been treated in total in the two Phase 1 studies, with preliminary signs of clinical activity observed in several patients.

Affimed (AFMD) will be working closely with the global health authorities, the Safety Monitoring Committees, and the studies' clinical investigators to review the events, carefully assess all of the data and determine next steps for the AFM11 program. Affimed(AFMD) intends to provide an update on AFM11 upon completion of the evaluation.

The clinical hold does not affect the ongoing development of Affimed's(AFMD) NK cell engager programs, which are based on targeting the NK cell receptor CD16A, a different approach than used for AFM11, which targets T cells through CD3.

About Affimed N.V.(AFMD)
Affimed (AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements appear in a number of places throughout this release and include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, the value of our ROCK® platform, our ongoing and planned preclinical development and clinical trials, our collaborations and development of our products in combination with other therapies, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, our intellectual property position, our collaboration activities, our ability to develop commercial functions, expectations regarding clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies, the industry in which we operate, the trends that may affect the industry or us and the risks, uncertainties and other factors described under the heading "Risk Factors" in Affimed's(AFMD) filings with the Securities and Exchange Commission. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

Affimed Investor Contact:
Gregory Gin, Head of Investor Relations
E-Mail: IR@affimed.com

Affimed Media Contact:
Anca Alexandru, Head of Communications, EU IR
E-Mail: media@affimed.com

Image: Affimed(AFMD) logo.jpg

Source: Affimed N.V.(AFMD)
2018 GlobeNewswire, Inc.

" Money talks and bullshit walks "
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist